NOVEL DRUG DISCOVERY & DEVELOPMENT (NDDD)
Lupin’s strong NDDD team has built a pipeline of over 10 highly differentiated and innovative new chemical entities in therapies such as CNS disorders, Oncology, Immunology, Pain & Inflammation and Metabolic disorders.
Key Targets & Status
- CNS: Clinical Phase-II efficacy study in Alzheimer’s disease patients is progressing well in Europe; study to be completed this year.
- Cancer: Clinical Phase-I study successfully completed in Europe in terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer).
- Endocrine: Best-in-class 2nd generation “Precision Calcimimetic” for Chronic Kidney Disease (CKD) and Primary Hyperparathyroidism (PHPT). PhEndocrine: Clinical Phase-I study successfully completed in Europe meeting approvable primary end-point.
- Immunology: Clinical Phase-I study successfully completed in Europe. Two proofs of concept Phase-II studies in Europe (Rheumatoid Arthritis and Psoriasis) have been initiated. We have the potential to be the first-in-class in this area.